Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer

Molecular Immunology

Volumn 48, Issue 4, 2011, Pages 431-441

  Campana, Raffaela ^a   Vrtala, Susanne ^a   Maderegger, Bernhard ^b   Dall'Antonia, Yuliya ^c   Zafred, Domen ^c   Blatt, Katharina ^a   Herrmann, Harald ^a   Focke Tejkl, Margarete ^a   Swoboda, Ines ^a   Scheiblhofer, Sandra ^d   Gieras, Anna ^a   Neubauer, Angela ^b   Keller, Walter ^c   Valent, Peter ^a   Thalhamer, Josef ^d   Spitzauer, Susanne ^a   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIOMAY AG   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Immunotherapy; Protein aggregation; RBet v 1; Recombinant hypoallergenic molecules

Indexed keywords

EPITOPE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BIRCH; CIRCULAR DICHROISM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GEL FILTRATION; HUMAN; HYPOALLERGENIC ACTIVITY; IMMUNOASSAY; IMMUNOTHERAPY; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLLEN ALLERGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, PLANT; BASOPHILS; BETA-N-ACETYLHEXOSAMINIDASES; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; PHOSPHORIC DIESTER HYDROLASES; PROTEIN STRUCTURE, QUATERNARY; PYROPHOSPHATASES; RATS; RECOMBINANT PROTEINS; SOLUTIONS; UP-REGULATION;

EID: 78650590515     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.09.016     Document Type: Article

References (29)

1. Bernstein D.I., Wanner M., Orish L., Liss G.M. Immunotherapy Committee, American Academy of Allergy. Asthma and Immunology, 2004. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004, 113:1129-1136.
2. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 1998, 102:558-562.
3. Durham S.R., Till S.J. Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 1998, 102:157-164.
4. Fedorov A.A., Ball T., Mahoney N.M., Valenta R., Almo S.C. The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 1997, 15:33-45.
5. Ferreira F., Hirtenlehner K., Jilek A., Godnik-Cvar J., Breiteneder H., Grimm R., Hoffmann-Sommergruber K., Scheiner O., Kraft D., Breitenbach M., Rheinberger H.J., Ebner C. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 1996, 183:599-609.
6. Ferreira F., Ebner C., Kramer B., Casari G., Briza P., Kungl A.J., Grimm R., Jahn-Schmid B., Breiteneder H., Kraft D., Breitenbach M., Rheinberger H.J., Scheiner O. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 1998, 12:231-242.
7. Flicker S., Vrtala S., Steinberger P., Vangelista L., Bufe A., Petersen A., Ghannadan M., sperr W.R., Valent P., Norderhaug L., Bohle B., Stockinger H., Suphioglu C., Ong E.K., Kraft D., Valenta R. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. J. Immunol. 2000, 165:3849-3859.
8. Flicker S., Steinberger P., Ball T., Krauth M.T., Verdino P., Valent P., Almo S., Valenta R. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J. Allergy Clin. Immunol. 2006, 117:1336-1343.
9. Fling S.P., Gregerson D.S. Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. Anal. Biochem. 1986, 155:83-88.
10. Hauswirth A.W., Natter S., Ghannadan M., Majlesi Y., Schernthaner G.H., Sperr W.R., Bühring H.J., Valenta R., Valent P. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J. Allergy Clin. Immunol. 2002, 110:102-109.
11. Hoffmann-Sommergruber K., Susani M., Ferreira F., Jertschin P., Ahorn H., Steiner R., Kraft D., Scheiner O., Breiteneder H. High-level expression and purification of the major birch pollen allergen, Bet v 1. Protein Expr. Purif. 1997, 9:33-39.
12. Kahlert H., Suck R., Weber B., Nandy A., Wald M., Keller W., Cromwell O., Fiebig H. Characterization of hypoallergenic recombinant Bet v 1 variant as a candidate of allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 2008, 145:193-206.
13. Laffer S., Vangelista L., Steinberger P., Kraft D., Pastore A., Valenta R. Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1. J. Immunol. 1996, 157:4953-4962.
14. Laffer S., Hogbom E., Roux K.H., Sperr W.R., Valent P., Bankl H.C., Vangelista L., Kricek F., Kraft D., Grönlind H., Valenta R. A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-Fce{open}RI interaction and reacts with receptor-bound IgE. J. Allergy Clin. Immunol. 2001, 108:409-416.
15. Larché M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 2006, 6:761-771.
16. Marsh D.G., Lichtenstein L.M., Campbell D.H. Studies on 'Allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970, 18:705-722.
17. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., Reisinger J., Pelzmann M., Hayek B., Kronqvist M., Gafvelin G., Grönlund H., Purohit A., Suck R., Fiebig H., Cromwell O., Pauli G., van Hage-Hamsten M., Valenta R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. U.S.A. 2004, 2:14677-14682.
18. Schöll I., Kalkura N., Shedziankova Y., Bergmann A., Verdino P., Knittelfelder R., Kopp T., Hantusch B., Betzel C., Dierks K., Scheiner O., Boltz-Nitulescu G., Keller W., Jensen-Jarolim E. Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. J. Immunol. 2005, 175:6645-6650.
19. Sellge G., Laffer S., Mierke C., Vrtala S., Hoffmann M.W., Klempnauer J., Manns M.P., Valenta R., Bischoff S.C. Development of an in vitro system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: Fce{open} receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergic reactions. Clin. Exp. Allergy 2005, 35:774-781.
20. Spangfort M.D., Mirza O., Ipsen H., van Neerven R.J., Gajhede M., Larsen J.N. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J. Immunol. 2003, 171:3084-3090.
21. Valenta R., Ferreira F., Focke-Tejkl M., Linhart B., Niederberger V., Swoboda I., Vrtala S. From allergen genes to allergy vaccines. Annu. Rev. Immunol. 2010, 28:211-241.
22. van Hage-Hamsten M., Kronqvist M., Zetterström O., Johansson E., Niederberger V., Vrtala S., Grönlund H., Grönneberg R., Valenta R. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol. 1999, 104:969-977.
23. Vrtala S., Hirtenlehner K., Vangelista L., Pastore A., Eichler H.G., Sperr W.R., Valent P., Ebner C., Kraft D., Valenta R. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Invest. 1997, 99:1673-1681.
24. Vrtala S., Akdis C.A., Budak F., Akdis M., Blaser K., Kraft D., Valenta R. The cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol. 2000, 165:6653-6659.
25. Vrtala S., Hirtenlehner K., Susani M., Akdis M., Kussebi F., Akdis C.A., Blase K., Hufnagl P., Binder B.R., Politou A., Pastore A., Vangelista L., Sperr W.R., Semper H., Valent P., Ebner C., Kraft D., Valenta R. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen. Bet v 1. FASEB J. 2001, 15:2045-2057.
26. Vogel L., Lüttkopf D., Hatahet L., Haustein D., Vieths S. Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system. Allergy 2005, 60:1021-1028.
27. Whitmore L., Wallace B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 2004, 32:668-673.
28. Wiedemann P., Giehl K., Almo S.C., Fedorov A.A., Girvin M., Steinberger P., Rüdiger M., Ortner M., Sippl M., Dolecek C., Kraft D., Jockusch B., Valenta R. Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody. J. Biol. Chem. 1996, 271:29915-29921.
29. Winther L., Arnved J., Malling H.J., Nolte H., Mosbech H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy 2006, 36:254-260.